S&P Equity Research downgrades Idenix Pharmaceuticals (Nasdaq: IDIX) from Buy to Hold.

S&P analyst, J. Loo, says, "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE